GATA6 inhibits the biological function of non-small cell lung cancer by modulating glucose metabolism.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
14 Mar 2024
Historique:
received: 28 01 2024
accepted: 23 02 2024
medline: 18 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: epublish

Résumé

This study aims to explore the role of GATA6 in lung cancer, with a focus on its impact on metabolic processes. We assessed GATA6 expression in lung cancer tissues and its association with patient prognosis. In vitro cell function experiments were conducted to investigate the effects of altered GATA6 levels on lung cancer cell proliferation and migration. Mechanistic insights were gained by examining GATA6's influence on glucose metabolism-related genes, particularly its effect on c-Myc mRNA expression. Our study revealed significant down-regulation of GATA6 in lung cancer tissues, and this down-regulation was strongly correlated with unfavorable patient prognosis. Elevating GATA6 levels effectively inhibited the proliferation and migration of lung cancer cells in our cell function experiments. Mechanistically, we found that GATA6 suppressed the expression of c-Myc mRNA, impacting genes related to glucose metabolism. As a result, glucose uptake and metabolism in lung cancer cells were disrupted, ultimately impeding their malignant behaviors. Our study provides crucial insights into the metabolic regulation of GATA6 in lung cancer cells. These findings have the potential to offer a solid theoretical foundation for the development of novel clinical treatments for lung cancer.

Identifiants

pubmed: 38483616
doi: 10.1007/s00432-024-05664-y
pii: 10.1007/s00432-024-05664-y
pmc: PMC10940364
doi:

Substances chimiques

RNA, Messenger 0
Glucose IY9XDZ35W2
GATA6 protein, human 0
GATA6 Transcription Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126

Subventions

Organisme : Joint Fund Program Project of Liaodong University Research Fund
ID : 2022YB004
Organisme : Education Department in Liaoning Province
ID : LJKMZ20221762

Informations de copyright

© 2024. The Author(s).

Références

J Mater Chem B. 2023 Jun 28;11(25):5715-5747
pubmed: 37264815
Semin Cancer Biol. 2022 Aug;83:166-176
pubmed: 33220458
Exp Mol Pathol. 2015 Dec;99(3):617-27
pubmed: 26505174
Nat Rev Clin Oncol. 2023 Oct;20(10):664-677
pubmed: 37488229
Front Oncol. 2020 Jun 12;10:824
pubmed: 32596145
J Thorac Oncol. 2023 Apr;18(4):410-418
pubmed: 36572339
IUBMB Life. 2020 Jan;72(1):39-44
pubmed: 31778014
IUBMB Life. 2020 Jan;72(1):10-26
pubmed: 31574210
Development. 2018 Oct 22;145(20):
pubmed: 30348673
Oncol Lett. 2018 Jul;16(1):247-252
pubmed: 29928408
Hum Pathol. 2019 Apr;86:163-169
pubmed: 30633927
Biochem Genet. 2023 Apr;61(2):578-596
pubmed: 36001185
Hum Cell. 2024 Jan;37(1):271-284
pubmed: 37768544
Front Cell Dev Biol. 2017 Apr 11;5:35
pubmed: 28443280
Biomedicines. 2021 Mar 15;9(3):
pubmed: 33803938
JAMA Netw Open. 2020 Jun 1;3(6):e206368
pubmed: 32492160
Int J Biol Macromol. 2020 Dec 1;164:1294-1303
pubmed: 32698071
Mediators Inflamm. 2023 May 26;2023:9340499
pubmed: 37273453
Cancer Cell. 2013 Jun 10;23(6):725-38
pubmed: 23707782
Drug Discov Today. 2020 May;25(5):891-900
pubmed: 32105718
Exp Ther Med. 2022 Apr;23(4):281
pubmed: 35317445
Cancer Treat Rev. 2021 Mar;94:102154
pubmed: 33524794
Sci Rep. 2017 Jul 6;7(1):4770
pubmed: 28684780
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4347-4357
pubmed: 32041891
Oncogene. 2020 Apr;39(18):3726-3737
pubmed: 32157212
Cancer Biol Ther. 2019;20(9):1206-1212
pubmed: 31092103
Oncol Lett. 2021 Oct;22(4):718
pubmed: 34429758

Auteurs

Weiwei Ju (W)

Institute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.

Lijuan Lin (L)

Institute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.

Qifang Zhang (Q)

Institute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.

Xiumei Lv (X)

Institute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.

Shaohui Teng (S)

Institute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.

Yu Hong (Y)

Institute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.

Zhixiang Shao (Z)

Pathology Department, Dandong First Hospital, Dandong, 118003, China.

Hanyun Na (H)

Pathology Department, Dandong First Hospital, Dandong, 118003, China.

Shengjin Yu (S)

Institute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China. yubing557@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH